Drug Combination Details
| General Information of the Combination (ID: C48730) | |||||
|---|---|---|---|---|---|
| Name | Ursolic acid NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Kaposi sarcoma
[ICD-11: 2B57]
|
Investigative | [1] | ||
|
Breast cancer
[ICD-11: 2C60]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Activity | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SW982 | CVCL_1734 | Biphasic synovial sarcoma | Homo sapiens | ||
| SK-UT-1 | CVCL_0533 | Uterine corpus leiomyosarcoma | Homo sapiens | |||
| HT-1080 | CVCL_0317 | Fibrosarcoma | Homo sapiens | |||
| Experimental
Result(s) |
Down-regulation of AKT signalling by ursolic acid induces intrinsic apoptosis and sensitization to doxorubicin in soft tissue sarcoma. | |||||
| Experiment 2 Reporting the Effect of This Combination | [2] | |||||
| Biological
Regulation |
Disruption | Glutamine metabolism | ||||
| Disruption | Synthesis of amino acids | |||||
| Down-regulation | P-gp efflux | |||||
| Disruption | Glycolysis | |||||
| Disruption | TCA cycle | |||||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Combination of UA and Dox could reverse the MDR in breast cancer cells by inhibition of P-gp function and disruption of the metabolism of energy and related amino acids. | |||||
